Bryan Cox
Director Técnico/Científico/I+D en TRISALUS LIFE SCIENCES, INC. .
Fortuna: 620 743 $ al 31/05/2024
Perfil
Bryan F.
Cox is currently the Chief Executive Officer at Nephraegis Therapeutics, Inc. and the Chief Scientific & Manufacturing Officer at TriSalus Life Sciences, Inc. Previously, he worked as the Director-Integrative Pharmacology at Abbott Laboratories from 1996 to 2013.
Dr. Cox holds a doctorate degree from the University of Iowa and an undergraduate degree from The University of North Carolina at Chapel Hill.
Participaciones conocidas en empresas públicas
| Empresa | Fecha | Número de acciones | Valoración | Fecha de valoración |
|---|---|---|---|---|
| 12/02/2024 | 86 696 ( 0.32% ) | 620 743 $ | 31/05/2024 |
Cargos activos de Bryan Cox
| Empresas | Cargo | Inicio |
|---|---|---|
| TRISALUS LIFE SCIENCES, INC. | Director Técnico/Científico/I+D | 10/08/2023 |
Nephraegis Therapeutics, Inc.
 Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Director Ejecutivo | 01/11/2018 |
Antiguos cargos conocidos de Bryan Cox.
| Empresas | Cargo | Fin |
|---|---|---|
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/01/2013 |
Formación de Bryan Cox.
| University of Iowa | Doctorate Degree |
| The University of North Carolina at Chapel Hill | Undergraduate Degree |
Experiencias
Funciones ocupadas
Relaciones
Relaciones de 1er grado
Empresas vinculadas al 1er grado
Hombre
Mujer
Administradores
Ejecutivos
Empresas relacionadas
| Empresas cotizadas | 2 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| TRISALUS LIFE SCIENCES, INC. | Health Technology |
| Empresas privadas | 1 |
|---|---|
Nephraegis Therapeutics, Inc.
Nephraegis Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Nephraegis Therapeutics is a biopharmaceutical company based in Lake Forest, IL. Nephraegis Therapeutics, Inc. focuses on targeting acute kidney injury (AKI) through the development of a family of proprietary drug candidates. The company's lead compound, NPH-022, is an epoxyeicosatrienoic-related compound (EET) with optimized pharmacokinetic properties. The company was founded by Richard B. Marshak, and Bryan F. Cox has been the CEO since 2018. | Health Technology |
- Bolsa de valores
- Insiders
- Bryan Cox
